Cellectis S.A.

EPA:ALCLS.PA

1.69 (EUR) • At close November 7, 2024
Bedrijfsnaam Cellectis S.A.
Symbool ALCLS.PA
Munteenheid EUR
Prijs 1.688
Beurswaarde 121,693,997
Dividendpercentage 0%
52-weken bereik 1.634 - 3.44
Industrie Biotechnology
Sector Healthcare
CEO Dr. Andre Choulika Ph.D.
Website https://www.cellectis.com

An error occurred while fetching data.

Over Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies,

Vergelijkbare Aandelen

DBV Technologies S.A. logo

DBV Technologies S.A.

DBV.PA

2.136 EUR

MedinCell S.A. logo

MedinCell S.A.

MEDCL.PA

17.6 EUR

UG Healthcare Corporation Limited logo

UG Healthcare Corporation Limited

8K7.SI

0.123 SGD

Genfit S.A. logo

Genfit S.A.

GNFT.PA

5.39 EUR

Nanobiotix S.A. logo

Nanobiotix S.A.

NANO.PA

3.93 EUR

Median Technologies SA logo

Median Technologies SA

ALMDT.PA

4.33 EUR

Amplitude Surgical SA logo

Amplitude Surgical SA

AMPLI.PA

3.16 EUR

Malin Corporation plc logo

Malin Corporation plc

MLC.IR

5.8 EUR

OSE Immunotherapeutics SA logo

OSE Immunotherapeutics SA

OSE.PA

10.06 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)